| Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis T Makunts, IV Cohen, L Awdishu, R Abagyan Scientific reports 9 (1), 2282, 2019 | 70 | 2019 |
| Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory T Makunts, S Alpatty, KC Lee, RS Atayee, R Abagyan Scientific reports 9 (1), 17280, 2019 | 65 | 2019 |
| Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids T Makunts, A U, RS Atayee, R Abagyan Scientific reports 9 (1), 12490, 2019 | 43 | 2019 |
| Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications IV Cohen, T Makunts, R Atayee, R Abagyan Scientific reports 7 (1), 1450, 2017 | 38 | 2017 |
| Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites T Makunts, MA Wollmer, R Abagyan Scientific reports 10 (1), 12851, 2020 | 31 | 2020 |
| Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data T Makunts, IM Saunders, IV Cohen, M Li, T Moumedjian, MA Issa, ... Scientific reports 11 (1), 17324, 2021 | 27 | 2021 |
| Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain T Makunts, IV Cohen, KC Lee, R Abagyan PLoS One 13 (4), e0195521, 2018 | 22 | 2018 |
| Common osteoporosis drug associated with increased rates of depression and anxiety D Keshishi, T Makunts, R Abagyan Scientific reports 11 (1), 23956, 2021 | 21 | 2021 |
| Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database IV Cohen, T Makunts, R Abagyan, K Thomas Scientific reports 11 (1), 5997, 2021 | 20 | 2021 |
| Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety MA Wollmer, T Makunts, THC Krüger, R Abagyan Scientific reports 11 (1), 24173, 2021 | 16 | 2021 |
| Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports IV Cohen, T Makunts, T Moumedjian, MA Issa, R Abagyan Scientific reports 10 (1), 19199, 2020 | 16 | 2020 |
| Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events T Makunts, K Burkhart, R Abagyan, P Lee PloS one 17 (2), e0263402, 2022 | 7 | 2022 |
| Reported cases of serotonin syndrome in MDMA users in FAERS database T Makunts, L Jerome, R Abagyan, A de Boer Frontiers in Psychiatry 12, 2022 | 7 | 2022 |
| Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data H Joulfayan, T Makunts, R Abagyan Scientific reports 13 (1), 10448, 2023 | 5 | 2023 |
| How can proton pump inhibitors damage central and peripheral nervous systems? T Makunts, R Abagyan Neural Regeneration Research 15 (11), 2041-2042, 2020 | 5 | 2020 |
| Determinants of cardiac adverse events of chloroquine and hydroxychloroquine in 20 years of drug safety surveillance reports IV Cohen, T Makunts, T Moumedjian, M Issa, R Abagyan medRxiv, 2020.05. 19.20107227, 2020 | 4 | 2020 |
| Divergent mechanisms for regulating growth and development after imaginal disc damage in the tobacco hornworm, Manduca sexta MA Rosero, B Abdon, NJ Silva, B Cisneros Larios, JA Zavaleta, T Makunts, ... Journal of Experimental Biology 222 (20), jeb200352, 2019 | 3 | 2019 |
| Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events T Makunts, S Grabska, H Grabski, R Abagyan medRxiv, 2024.02. 14.24302840, 2024 | 1 | 2024 |
| Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA Adverse Event Reporting System T Makunts, D Dahill, L Jerome, A de Boer, R Abagyan Frontiers in Psychiatry 14, 812, 2023 | 1 | 2023 |
| Depression events associated with proton-pump inhibitors in postmarketing drug surveillance data T Makunts, H Joulfayan, K Ta, R Abagyan Pharmacoepidemiology 2 (3), 272-282, 2023 | | 2023 |
Isaac V Cohen, PharmDDenali TherapeuticsVerified email at dnli.com
